Rock Weekly: 23andMe makes up with the FDA
June 23, 2014
The FDA is up to their neck in digital health. First, in a rare move, they announced they’ll be hands-off with certain mobile medical apps that happen to resemble HealthKit. Then they told pharma and medical device companies what they can and can’t tweet. They finished the week off by launching a review into a new 510(k) application—this time from 23andMe as part of its first step to re-enter healthcare.
Want to train your brain in the art of digital health company building? Check out our Startup Elements series, where luminaries drop knowledge about everything from IP and accounting to HIPAA and the FDA.
You’re missing out. Get the most important newsletter in digital health delivered to your inbox.
The Wall Street Journal
Rock Health In The News
|ClearCare||$11M||Bessemer Venture Partners, Cambia Health Solutions, Voyager Capital, Qualcomm Ventures, Harbor Pacific Capital||VentureBeat|
|Peloton Interactive||$10.5M||Tiger Global||peHUB|
|Augmedix||$7.3M||DCM, Emergence Capital Partners||San Francisco Chronicle|
|Valencell||$7M||WSJ Joshua Fund, TDF Ventures, True Ventures, Best Buy Capital||MobiHealthNews|
|MDSave||$2M||Undisclosed||Nashville Business Journal|
|Calm.com||$578K||Launch, Matt Mullenweg, Matt Cheng||TechCrunch|
Interested in a full roundup of digital health funding deals since 2011? Get our funding database. You’re missing out. Get the most important newsletter in digital health delivered to your inbox.